Navigation Links
AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
Date:6/8/2009

yeloma and metastatic colon cancer where, unlike the non-small cell lung cancer study design, perifosine is dosed 50mg or 100mg daily until progression. Recently, positive Phase 2 data for multiple myeloma and metastatic colon cancer were presented at ASH and ASCO meeting, respectively."

About Perifosine

Perifosine is a novel, first-in-class, oral anti-cancer agent that modulates several key signal transduction pathways, including Akt, MAPK, and JNK that have been shown to be critical for the survival of cancer cells. Perifosine has demonstrated single agent anti-tumor activity in Phase 1 and Phase 2 studies and is currently being studied as a single agent and in combination with several forms of anti-cancer treatments for various forms of cancer. Most recently, positive results were reported for the single agent use of perifosine in patients with advanced metastatic renal cancer and in combination with capecitabine for advanced metastatic colon cancer (placebo-controlled), as well as for perifosine in combination with bortezomib +/- dexamethasone in relapsed and refractory myeloma.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources t
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... The Global and China Diabetes Drugs Industry is ... of the Diabetes Drug industry in Global and China. ... industry, including definitions, applications and industry chain structure. Global ... with a focus on history, developments, trends and competitive ... and Chinese situation is also offered. , The report ...
(Date:8/22/2014)... -- Research and Markets has announced the ... & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market ... The global molecular biology enzymes market ... expected to grow at a CAGR of 13.74% to ... & reagents find applications in a large number of ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Nerium ... products, is in the spotlight again. Nerium will ... and its NeriumFirmTM Body Contouring Cream to Hollywood’s ... Backstage Creations during the 66th Primetime Emmy® Awards. ... NAE-8® extract, third-party clinical trials show that NeriumAD ...
(Date:8/22/2014)... Greenville, SC (PRWEB) August 22, 2014 ... that indisputable acknowledgement is a national disgrace. Furthermore, ... part in establishing the current, deplorable state of ... outlined "5 great mistakes," to merely serve as ... convey the extent of colossal failure(s) that have ...
Breaking Biology Technology:Diabetes Drugs Industry Growth Analysis in Global, China Regions Research Report Available at DeepResearchReports.com 2Diabetes Drugs Industry Growth Analysis in Global, China Regions Research Report Available at DeepResearchReports.com 3Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 35 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2
... FRANCISCO, Calif., Aug. 7 Anesiva,Inc. (Nasdaq: ANSV ... quarter and six months ended June 30, 2008., ... Anesiva as we,introduced Zingo(TM) in the U.S. pediatric hospital ... "In addition, I,m pleased,to report that our Phase 3 ...
... Inc.,(Nasdaq: ITMN ) today announced that Daniel G. ... the Canaccord Adams 28th Annual,Global Growth Conference in Boston ... To access a live audio webcast of the presentation, ... investor relations page of InterMune,s,corporate website at http://www.intermune.com ...
... 7 Medicsight PLC, a subsidiary,of MGT Capital ... industry leader in the,development of Computer-Aided Detection (CAD) ... received approval from the Brazilian regulatory,agency, Agencia Nacional ... David Sumner, Chief Executive of Medicsight, commented: "This ...
Cached Biology Technology:Anesiva Announces Second Quarter 2008 Financial Results and Update 2Anesiva Announces Second Quarter 2008 Financial Results and Update 3Anesiva Announces Second Quarter 2008 Financial Results and Update 4Anesiva Announces Second Quarter 2008 Financial Results and Update 5Anesiva Announces Second Quarter 2008 Financial Results and Update 6Anesiva Announces Second Quarter 2008 Financial Results and Update 7Anesiva Announces Second Quarter 2008 Financial Results and Update 8Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software 2Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software 3
(Date:8/22/2014)... basic and clinical research and technological advances, the ... offensive spanning multiple fronts. , Work happening in ... find new and more selective therapies for cancer. ... specific enzyme overexpressed in certain cancersand they have ... , Chemistry professor Christopher Cairo and his team ...
(Date:8/22/2014)... American consumers will finally be able to purchase fuel ... as zero-emissions vehicles, most of the cars will run ... that contributes to global warming. , Now scientists at ... uses an ordinary AAA battery to produce hydrogen by ... through two electrodes that split liquid water into hydrogen ...
(Date:8/21/2014)... Nxt-ID, Inc. (OTCQB: NXTD), a biometric authentication ... today that its shares of common stock and the ... its proposed underwritten public offering of common stock and ... Capital Market, subject to closing of its proposed underwritten ... will trade under the symbol "NXTD" and "NXTDW," respectively. ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3
... warming in alpine regions is putting pressure on a rare ... released in Climatic Change Letters . In ... of Montana, U.S. Fish and Wildlife Service and National Park ... warning indicators of climate warming in mountain ecosystems. The glaciers ...
... Coastal mangrove forests store more carbon than almost any ... by a team of U.S. Forest Service and university ... Nature Geoscience . ( www.nature.com/naturegeoscience.com ) A ... and Northern research stations, University of Helsinki and the ...
... (April 4, 2011) An international team of researchers ... alcohol consumption, according to a new study published online ... of the National Academy of Sciences . ... that influence alcohol drinking behavior. Study contributors Danielle ...
Cached Biology News:Mangroves among the most carbon-rich forests in the tropics 2Gene involved in predisposition to alcohol consumption identified 2
... is a completely redesigned and updated version ... accepts the full line of well-proven Alpha ... in thermal performance as the DNA Engine ... easy transport of protocols among platforms. ...
... or for use in an automated line. ... disposable manifold provides greater ease, speed, convenience, ... StatMatic II can be connected to a ... fill a microplate with one-handed operation -- ...
... is a completely redesigned and updated version ... accepts the full line of well-proven Alpha ... in thermal performance as the DNA Engine ... easy transport of protocols among platforms. The ...
... standards consist of seven reduced, denatured proteins ... anhydrase, rabbit muscle GAPDH, bovine muscle actin, ... pIs ranging from 4.5 to 8.5 and ... These 2-D standards provide calibrated references for ...
Biology Products: